SURFACE IS
NOT STRUCTURE.

DIFFERENT QUESTIONS. DIFFERENT TOOLS.

Patients commonly use broad phrases. "My skin looks tired." "My face looks older." "My skin doesn't look as smooth." "My jawline isn't what it used to be." "I just want everything tighter."

Those statements may describe multiple anatomical and skin-quality changes at once. A single sentence can contain pigment, texture, fine lines, laxity, and volume change. Treatment begins by separating them. Skin resurfacing and skin tightening are not the same thing, and asking one device to solve every concern is how plans become imprecise.

Skin resurfacing and skin tightening are not the same thing.

Different treatments interact with different levels and mechanisms. ULTRA addresses a surface and resurfacing conversation. XERF addresses a firmness and structural conversation. Understanding the layer is what makes the plan coherent rather than random.

Surface concerns are what light reveals when it moves across the skin. Pigmentation, roughness, visible pores, fine texture, photodamage, selected fine lines, and selected acne marks or scars where appropriate. These are the qualities you notice in raking light, in a mirror tilted toward a window, or in the texture of a photograph.

ULTRA belongs to this conversation. As a 1927 nm non-ablative fractional thulium laser, it creates controlled micro-injury in the superficial skin to support resurfacing-related goals. Surface treatment does not tighten loose skin, and it should not be expected to.

For this article, structure refers primarily to firmness, laxity, how skin drapes, jawline softness, jowling appearance, and neck laxity. It is about how the skin holds itself, not what it looks like in raking light.

XERF belongs to this conversation. It uses multifrequency monopolar radiofrequency energy to support a firmness and structural skin-tightening category. Structural treatment does not resurface pigment, and it should not be expected to.

ULTRA refers to the LaseMD Ultra, a 1927 nm non-ablative fractional thulium laser manufactured by Lutronic (Cynosure Lutronic). It delivers fractional laser energy to create controlled micro-channels in the skin, supporting a resurfacing and skin-quality conversation. It is FDA-cleared for dermatologic procedures including the coagulation of soft tissue and treatment of selected pigmentation concerns.

ULTRA is a laser. It is not radiofrequency. It is not a skin-tightening device. Its verified applications, depending on JOLA protocol, may include selected pigmentation, texture, pore appearance, fine lines, and acne-related surface changes.

XERF is a non-invasive structural skin-tightening system manufactured by Lutronic (Cynosure Lutronic). It uses multifrequency monopolar radiofrequency energy, combining 6.78 MHz and 2 MHz frequencies, to deliver heat to tissue in a firmness and structural tightening conversation. It does not use needles and does not use laser energy.

XERF is radiofrequency. It is not a laser. It is not a resurfacing treatment. Its verified clinical positioning, depending on JOLA protocol, relates to skin firmness, laxity, and structural support in appropriate treatment areas.

XERF is radiofrequency. ULTRA is a laser. They are not interchangeable.

A meaningful comparison requires specification, not ranking. The table below uses APPROPRIATE, NOT PRIMARY TARGET, and DEPENDS where nuance matters rather than simplistic checks.

Asking "which is better?" without defining the concern is like asking whether a surface finish or structural reinforcement is better in architecture. They solve different problems. ULTRA and XERF do not need to compete. They have different jobs.

A tool cannot win a job it was not designed to do.

Ranking them against each other without naming the concern produces a meaningless answer. The right question is which tool fits which layer of the problem.

ULTRA may belong to a selected pigmentation conversation where supported by indication and JOLA protocol. As a 1927 nm fractional laser, it interacts with superficial pigment in a resurfacing context. XERF should not be positioned as a pigmentation treatment. Radiofrequency is not a pigment-targeting energy.

If pigmentation is the primary concern, the conversation belongs to ULTRA for pigmentation, not to a combination plan by default.

Sun damage can include brown spots, texture changes, fine lines, and elasticity changes. Some components belong to a resurfacing conversation. Other age-related changes may involve firmness. A patient with significant photodamage and early laxity may have two separate concerns, but a patient with photodamage alone may not.

Explore ULTRA for sun damage for the surface component.

Texture belongs primarily to a surface-quality conversation. Roughness, visible pores, and surface irregularity are what light reveals. ULTRA addresses this layer. XERF addresses how the skin sits, not how it feels to raking light.

Explore ULTRA for texture and pores.

Pores are surface anatomy. Neither treatment deletes pores. ULTRA may address the appearance of texture and pores where supported, because it belongs to the resurfacing conversation. XERF should not be sold as a pore treatment simply because it improves firmness. Firmness and pore appearance are different conversations.

Acne marks are not one thing. Brown marks and red marks are different. Brown marks involve pigment and may belong to a resurfacing conversation. Red marks involve a vascular component and may require a different approach. Structural scars are a separate conversation from both.

XERF is not a substitute for pigment-specific treatment. Explore ULTRA for acne marks and scars.

Scar morphology matters. A rolling scar, a boxcar scar, and an ice-pick scar are not the same plan. ULTRA may belong to selected scar and resurfacing plans where supported. XERF should not automatically be positioned as a scar resurfacing treatment, because radiofrequency firmness and surface scar remodeling are different conversations.

Fine lines can arise from surface aging, photodamage, movement, volume change, or laxity. Therefore ULTRA, XERF, Botox or Dysport, Sculptra, or other treatment categories may address different components of what a patient calls "lines."

A surface fine line from photodamage is not the same as a dynamic wrinkle from movement, and neither is the same as a line created by laxity. Naming the line is what makes the plan precise.

True laxity is different from roughness or pigmentation. If laxity is the primary issue, a resurfacing treatment should not automatically be expected to create the same type of result as a tightening-focused RF treatment. ULTRA addresses surface. XERF addresses firmness. Loose skin is a firmness conversation.

You cannot resurface your way out of laxity.

"Jowls" can involve skin laxity, fat distribution, volume change, facial anatomy, and skeletal structure. XERF may belong to the firmness conversation where appropriate, because jowling is fundamentally a structural concern. ULTRA does not tighten jowls. Do not claim XERF replaces surgery, because the degree of tissue descent matters.

Explore XERF for jowls and lower-face skin tightening.

Jawline appearance is multifactorial. Possible contributors include skin quality, laxity, volume, chin projection, jaw structure, and submental fullness. A laser cannot be expected to correct every contributor. XERF may belong to the firmness and laxity component where appropriate.

Explore XERF for jawline tightening and facial balancing where anatomy is the primary concern.

The neck may have pigmentation, crepey texture, horizontal lines, laxity, and photodamage. Different components may require different treatment categories. XERF may belong to the neck firmness conversation. ULTRA neck treatment should only be described if verified for that area in JOLA's protocol.

Explore XERF for neck tightening.

When a patient says their skin looks older, that sentence is the beginning of a diagnostic conversation, not the end of one. JOLA deconstructs the complaint before selecting a device.

A patient may simultaneously have surface irregularity and loss of firmness. In that situation, treating only the surface may leave the structural concern unchanged. Treating only firmness may leave pigmentation and texture unchanged. This is where combination planning may be considered.

But the combination exists because there are two concerns, not because two devices are better than one. Combination treatment should solve multiple problems, not simply use multiple devices.

Combination treatment should solve multiple problems. Not simply use multiple devices.

Concern A: brown spots and surface photodamage. Concern B: lower-face laxity. These should not automatically be assigned to one device. The brown spots belong to a surface and resurfacing conversation. The jowling belongs to a firmness and structural conversation.

This is a situation where ULTRA and XERF may each have a job. But the jobs must be named first.

Pores belong to the surface. Laxity belongs to the structure. They are different layers of the same face.

Scar treatment and tightening should be planned separately. Do not assume ULTRA is sufficient for every scar, and do not assume XERF is a scar treatment. Scar morphology determines the scar plan. Laxity determines the firmness plan. They may coexist, but they should not be collapsed into one device.

Surface lines, movement, and laxity are different. A fine line from photodamage, a dynamic wrinkle from expression, and a jowl from tissue descent each belong to a different treatment category. Treatment planning may involve more than two technologies.

The plan may include ULTRA for surface, a neuromodulator for movement, and XERF for firmness. Each has a job. The number of tools should never exceed the number of problems worth treating.

Not necessarily. If the primary issue is surface quality, ULTRA alone may be the relevant category. If the primary issue is laxity, XERF alone may be the relevant category. If both are clinically meaningful, a combined strategy may be considered.

More treatments is not the goal. More complete diagnosis is.

No. A patient whose primary concern is surface quality does not automatically need a firmness treatment. Adding XERF without a firmness indication is not a more complete plan. It is a more expensive one.

No. A patient whose primary concern is firmness does not automatically need a resurfacing treatment. Adding ULTRA without a surface indication does not improve the firmness result.

A combination may create a more comprehensive plan when there are multiple appropriate treatment targets. But adding an unnecessary treatment does not automatically improve an outcome. Comprehensive does not mean more. Comprehensive means complete.

Comprehensive ≠ more. Comprehensive = complete.

Whether same-day treatment is appropriate depends on treatment area, treatment intensity, skin response, recovery, and JOLA's clinical protocol. JOLA does not publish a universal same-day protocol. The sequence and spacing should be determined by the treating provider based on the patient's skin, treatment intensity, recovery, and goals.

There is no universal sequence. Potential considerations include the primary concern, skin condition, treatment intensity, downtime, event schedule, and provider strategy. The sequence should have a reason.

Sequence should have a reason.

Treatment spacing follows JOLA's clinical protocol and the patient's individual response. JOLA does not publish a universal interval, because the appropriate spacing depends on treatment intensity, area, recovery, and reassessment.

Healing, inflammation, skin response, assessment, and patient schedule may all affect sequencing. Treating too soon may interfere with the response window. Treating without a plan may produce two treatments that do not inform each other.

Potentially, if that is part of an individualized treatment plan. There is no universal cadence. Alternation, like any sequence, should have a clinical rationale.

ULTRA treatment count is response-based and depends on the concern, severity, skin, and goal. JOLA does not prescribe a universal number.

For the complete ULTRA treatment-count conversation, read How Many ULTRA Laser Treatments Do You Need?

XERF treatment count follows JOLA's protocol and current device guidance. The number depends on the firmness concern, treatment area, response, and goal. JOLA does not prescribe a universal number.

No. There is no reason the number should automatically match, because the technologies target different concerns. Do not create package arithmetic. The ULTRA count follows the surface concern. The XERF count follows the firmness concern.

Potentially for a particular patient's limited goals, but there is no universal formula. Response-led planning means the next session is informed by the response to the last one, not by a preset count.

ULTRA visible recovery and XERF expected recovery are different. ULTRA, as a non-ablative fractional laser, has minimal downtime relative to ablative resurfacing. XERF, as non-invasive RF, typically has minimal to no expected visible downtime.

Combination timing may affect the patient's calendar, but the two downtime profiles should not simply be added together. How they interact depends on sequence, spacing, and protocol. Read the ULTRA downtime guide for ULTRA-specific recovery detail.

That depends on the actual sequence and protocol. If treatments are spaced apart, the patient experiences each recovery separately. If timing varies, the experience varies. JOLA describes expected recovery based on the individual plan, not a universal combined downtime.

Surface treatment may require visible recovery. Firmness results may develop on another timeline. Therefore wedding planning should work backward from the desired endpoint, not simply from the procedure date. There is no arbitrary universal countdown. JOLA plans event-driven treatment with enough lead time for recovery and reassessment.

The same framework applies to any significant event. The endpoint determines the schedule. Treatment is planned backward from the date the skin should look settled, not forward from the date the patient first calls.

Sun exposure, pigment treatment, and recovery all interact. Vacation sun exposure can generate new damage, so timing and sun protection matter. JOLA does not invent restrictions, but patients should understand that treating pigment and then traveling to high UV exposure without protection undermines the result.

There is not one combined result date. ULTRA has its own response timeline. XERF has its own response timeline. The patient sees one face, but the plan may contain multiple clocks.

One plan can have multiple clocks.

ULTRA and XERF develop on different timelines because they address different layers. The patient experiences one face, but the plan tracks two clocks.

THE PATIENT SEES ONE FACE. THE PLAN MAY CONTAIN MULTIPLE TIMELINES.

Not mathematically. They may complement one another when they address different appropriate targets. Do not create the formula ULTRA + XERF = 2X result. That is invented arithmetic.

The value of combination treatment may come from addressing different concerns rather than one device biologically amplifying the other. JOLA does not claim biological synergy without evidence. The safer and often more useful concept is complementary targets.

The same principle applies. XERF does not biologically amplify ULTRA's resurfacing effect. Each treatment does its own job. The combination is valuable when both jobs are worth doing.

There are two possible meanings. Biologic synergy means one device biologically amplifies the other. Complementary treatment means two devices address different appropriate targets. Do not claim biologic synergy without evidence. For JOLA, the safer and often more useful concept is complementary targets.

Different jobs can create a more complete plan without claiming one device boosts the other.

Morpheus8 is RF microneedling. ULTRA is a laser. XERF is non-invasive RF. Therefore ULTRA + XERF should not simply be marketed as "a better Morpheus8." Different mechanisms, different delivery, different conversations.

Read the ULTRA vs. Morpheus8 comparison.

CO2 belongs to an ablative resurfacing category. ULTRA + XERF does not become equivalent to CO2 merely because two devices are used. A non-ablative fractional laser plus non-invasive RF is not the same as ablative resurfacing, and should not be represented as such.

Read the ULTRA vs. CO2 comparison.

Fraxel is a fractional laser brand family, not a single wavelength. XERF addresses a different RF and tightening conversation. ULTRA + XERF should not be positioned as a replacement for a specific Fraxel device without identifying which Fraxel and why.

Read the ULTRA vs. Fraxel comparison.

IPL and BBL belong primarily to selected pigment and vascular light-treatment conversations. ULTRA + XERF should not automatically replace a color-targeting technology. If the concern is primarily vascular or a specific pigment type, a different approach may be more appropriate.

Read the ULTRA vs. IPL/BBL comparison.

Traditional microneedling creates mechanical micro-injury. ULTRA is laser. XERF is RF. They are different mechanisms, not variations of the same treatment. ULTRA + XERF is not a substitute for mechanical microneedling when microneedling is the indicated approach.

Read the ULTRA vs. microneedling comparison.

If the concern is dynamic expression lines, neither ULTRA nor XERF necessarily replaces neuromodulators. Movement is a separate conversation from surface and firmness.

Explore neuromodulators and Botox at JOLA Dallas.

Sculptra belongs to a biostimulatory injectable and volume-support conversation. It is not resurfacing. It is not the same as non-invasive RF. Sculptra addresses volume and structural support through collagen stimulation over time, which is a different layer from both surface and firmness.

Explore Sculptra at JOLA Dallas.

A patient can theoretically have surface, firmness, and volume or biostimulation as separate treatment-planning categories. But each category must have an indication. This is not a "triple treatment." It is three named problems, each with its own tool.

The number of tools should never exceed the number of problems worth treating.

Explore XERF and Sculptra at JOLA Dallas.

Facial balancing addresses proportion, projection, volume, and structural relationships. ULTRA and XERF do not replace facial balancing when anatomy is the primary concern. Surface, firmness, and shape are different layers.

Explore facial balancing at JOLA Dallas.

Before choosing a device, JOLA asks four questions. The answers assign the layer, and the layer assigns the category.

The method moves from complaint to device in a deliberate order. Device selection is near the end, not the beginning.

Before adding a second treatment, JOLA asks ten questions. A treatment is added only if it has a job.

ULTRA alone may make sense when the primary concern is surface quality: texture, selected pigment, selected resurfacing goals, and related surface changes where supported by indication and JOLA protocol. This is not a remote diagnosis. It is a description of when one category is sufficient.

XERF alone may make sense when firmness or laxity is the dominant concern, and surface quality is not a meaningful independent target. This follows verified XERF indications and JOLA protocol.

ULTRA + XERF may make sense when there are meaningful surface concerns and meaningful firmness or laxity concerns, and both treatments are appropriate for the patient. Both categories must have an indication. Neither is added by default.

Sometimes neither ULTRA nor XERF is the right answer. A vascular issue may require another technology. A suspicious lesion requires medical evaluation. Active skin disease, severe acne, significant structural volume loss, surgical-level laxity, unrealistic expectations, or barrier compromise may all point elsewhere. Another treatment category may be more logical.

Good combination planning includes the option: none.

No universal claim. Non-surgical energy-based treatments should not be presented as equivalent to surgical lifting. The degree of laxity matters. For mild to moderate firmness concerns, XERF may belong to the conversation. For significant tissue descent, surgical consultation may provide information that energy-based treatment cannot.

For more significant tissue descent or laxity, surgical consultation may provide information that energy-based treatment cannot. JOLA does not discourage surgery. Surgery and energy-based treatment address different degrees of the same concern, and knowing where the line sits is part of honest planning.

Patients may encounter plans involving laser, RF, microneedling, injectables, facials, and peels all at once. More modalities do not automatically create more refined results. A plan can be complex, but it should never be random.

A sophisticated plan can be complex. It should never be random.

JOLA considers the exact concern, surface quality, pigmentation, texture, scars, fine lines, firmness, laxity, jawline, jowling, neck, skin tone, PIH history, sun exposure, previous laser, previous ULTRA, previous XERF, previous RF microneedling, previous IPL, previous CO2, injectables, skincare, barrier health, recovery tolerance, events, travel, budget, desired endpoint, and willingness to complete a staged plan.

None of that fits on a price list. It fits in a consultation.

Chey Cope is a laser specialist at JOLA Dallas. The role demands judgment at every step: device selection, laser planning, energy-based treatment planning, recognizing surface versus firmness concerns, knowing when another modality is more appropriate, treatment sequencing, and response assessment.

The question isn't how many devices we can use. It's how many problems we actually need to solve.

Editorial concept. Not a literal attributed quote unless approved.

The total cost depends on whether ULTRA alone, XERF alone, or a staged combination plan is actually appropriate. JOLA does not automatically bundle the treatments, and does not publish a multiplied combination price based on an invented protocol.

A combination plan should not begin with a package price. It should begin with a reason.

It may offer value when both technologies address distinct concerns the patient genuinely wants to improve. It may offer little value if the second treatment has no meaningful target. Worth is not measured by the number of devices. It is measured by whether each device has a job.

If you cannot explain the job of each treatment, the plan is not clear enough.

WHAT LAYER ARE YOU TREATING?

73 ANSWERS